Mutational analysis of the Janus kinase II (V617F) gene in patients with β-Thalassemia major

Salar A. Ahmed

doi:10.21271/ZJPAS.32.6.8

Authors

Salar A. Ahmed Department of Basic Sciences, College of Medicine, Hawler Medical University, Erbil- Iraq.

DOI:

https://doi.org/10.21271/ZJPAS.32.6.8

Keywords:

β-Thalassemia, JAK II, V617F mutation, Thromboembolic complications.

Abstract

β-Thalassemia is a group of congenital hemolytic anemia that characterized by the underproduction of the indispensable hemoglobin molecule, the oxygen and carbon dioxide carrying protein inside the red cells. With our current study, we’ve screened if some extent mutation at Valine 617 Phenylalanine of Janus kinase II genes detectable in β-thalassemia major in our region.

The present study for the screening of JAK II V617F mutation was conducted on (50) patients with β-thalassemia major, restriction fragment length polymorphism with restriction endonuclease enzyme AflIII was used to identify a flaking region of 617 for JAK II gene.

In the existing study, no mutation has been detected within the patients suffering from β-thalassemia major. Our results indicate that JAK II ^V617F mutation appears to not be associated with thromboembolic complications related to β-Thalassemia and therefore the incidence of β-Thalassemia. To the best of our knowledge, this study is the first evidence to determine the status of JAK II ^V617F mutation in patients with Thalassemia major in our region and expands the international published literature on it.

References

Ahmed, A., Güldal, M. 2019. Estimation of MDA, CRP and Some hematological parameters in the mature Cypriot Thalassemia patients. ZANCO Journal of Pure and Applied Sciences, 31(s4);143-149

Alabdulaali, MK. 2009. The role of JAK2 abnormalities in hematologic neoplasms. Hematology Reviews, 1(10): 56-61.

Ali, T., Zaher, K., Imad, U. and Maria, D. 2008. Thalassemia and hypercoagulability, Blood Reviews, 22(5):283-92. DOI: 10.1016/j.blre.2008.04.001

Al-Thwani, AN., Yaseen, NY. and Khaleel, KJ. 2010. The Role of JAK2 Mutation in Polycythaemia Vera in Some Iraqi Patients. Iraqi Journal of Cancer and Medical Genetics, 3(2): 42-45.

Amarapurkar, D., Punamiya, S., Patel, N., Parekh, S., Mehta, SH. And Shah, N. 2011. Prevalence of JAK2V617F mutation in intra-abdominal venous thrombosis. Tropical Gastroenterology, 32(4): 279–284.

Amiram, E. and Eliezer, A. 2002. The hypercoagulable state in thalassemia. Blood, 99(1):36-43.

Ataga, KI. 2009. Hypercoagulability and thrombotic complications in hemolytic anemias. Haematologica, 94(11): 1481-1484.

Cappellini, MD. 2007. Coagulation in the Pathophysiology of Hemolytic Anemias. American Society of Hematology, (1)74-78. DOI: 10.1182/asheducation-2007.1.74

Eldor, A., Rachmilewitz, EA. 2002. The hypercoagulable state in thalassemia. Blood, 99(1): 36-44. DOI: 10.3324/haematol.2009.013672

Faris, Q., and Dalal, S. 2019. Biochemical and Molecular analysis of the beta-globin gene on Saudi sickle cell anemia. Saudi Journal of Biological Science. 26(7):1377–1384. DOI: 10.1016/j.sjbs.2019.03.003.

Gregory, J., Martin, H., and Mark, T., 2017. Intravascular hemolysis and the pathophysiology of sickle cell disease. Journal of Clinical Investigation, 127(3): 750–760. DOI: 10.1172/JCI89741

Hadeer, A. and Omar, M. 2017. Ghallab Candidate markers for thromboembolic complications in adult Egyptian patients with β-thalassemia . The Egyptian Journal of Haematology, 42 (2):64-69. DOI: 10.4103/ejh.ejh_12_17

Karaköse, S., Oruç, N., Zengin, M., Akarca, US. and Ersöz, G. 2015. Diagnostic value of the JAK2 V617F mutation for latent chronic myeloproliferative disorders in patients with budd-chiari syndrome and/or portal vein thrombosis. Turkish Journal Gastroenterolgy, 26: 42-8.

Maria-Domenica, C., Khaled, M. and , Ali, T. 2011. Thalassemia as a Hypercoagulable State. Oncology & Hematology,7(2):157-60 DOI: doi.org/10.17925/OHR.2011.07.2.157

Melchiori, L. 2010, Jak2 eritropoeisi inefficacy in Beta-Talassemia. PhD. thesis. Università degli Studi di Padova.

Nihad, A. 2016. A study of some factors and certain hematological parameters in transfusion dependent beta thalassemia patients in Erbil Province, ZANCO Journal of Pure and Applied Sciences, 28 (s6); s89-s96

Sipahi, T., Kara, A., Kuybulu, A., Egin, Y. and Akar, N. 2009. Congenital Thrombotic Risk Factors in β-thalassemia. Clinical and Applied Thrombosis/Hemostasis,15(5): 581-584. DOI: 10.1177/1076029608316170.

Steensma, DP. 2006. JAK2 V617F in Myeloid Disorders: Molecular DiagnosticTechniques and Their Clinical Utility. Journal of Molecular Diagnostics, 8(4): 397-411.

Steensma, DP., Dewald, GW., Lasho, TL., Powell, HL., McClure, RF.and Levine, RL. 2005. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both “atypical” myeloproliferative disorders and myelodysplastic syndromes. Blood, 106(4): 1207-1210.

Syed, R., Sanjida S., and Islam, A. 2018. Clinical and Molecular Studies on Thalassemia . International Journal of Current Research and Review, 10(4). DOI: 10.7324/IJCRR.2018.1047

Vlackaki, E., Kalogeridis, A., Neokleous, N., Perifanis, V., Klonizakis, F., Ioannidou, E. and Klonizakis, L. 2012. Absence of Jak II ( V617F mutation in patients with beta thalassemia major and thrombocytosis due to splenectomy, Molecular Biology Report, 39:6101-6105. DOI: 10.1007/s11033-011-1425-7.